Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement

/PRNewswire/ -- Octapharma USA has submitted a Biologics License Application Supplement (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the...

Related Keywords

Germany ,United States ,Lachen ,Switzerland General ,Switzerland ,Sweden ,Austria ,France ,Willebrand ,Nordrhein Westfalen ,American ,Sigurd Knaub ,Alit Taher ,Claudia Khayat ,Katerynav Vilchevska ,Leonid Dubey ,Sylvia Werner ,Toshko Lissitchkov ,Dzmitry Novik ,Elina Peteva ,Flemming Nielsen ,Vladimir Vdovin ,Adlette Inati ,Margarita Arkadevna Timofeeva ,Robertf Sidonio Jr ,Centers For Disease ,Aflac Cancer Blood Disorders Center ,Octapharma Group ,Emory University School Of Medicine ,Drug Administration ,Octapharma United States Inc ,Biologics License Application Supplement ,Coagulation Factor ,Lyophilized Powder ,Intravenous Injection ,Octapharma United States President Flemming ,Investigator Robert ,Medical Director ,Aflac Cancer ,Blood Disorders Center ,Associate Professor ,Emory University School ,Octapharma United States ,Disease Control ,Willebrand Disease ,Ana Boban ,Csongor Kiss ,Plasma Derived Von Willebrand ,Previously Treated Patients ,Von Willebrand ,Century Road ,Octapharma Usa ,